—
New York, November 13, 2018: The Sunitinib Malate Market is expected to exceed more than US$ 129.5 Million by 2024 at a CAGR of 13.9% in the given forecast period.Market Research Engine has published a new report titled as “Sunitinib Malate Market By Product (Purity: 99%, Purity: 98%, Purity: 97%); By Application (Pancreatic Neuroendocrine Tumours, Kidney Cancer, Gastrointestinal stromal Tumour) and by Regional Analysis - Global Forecast by 2018 – 2024.”
Browse Full Report: https://www.marketresearchengine.com/sunitinib-malate-market
The Sunitinib Malate Market is segmented on the lines of its product, application and regional. On the basis of product, it is segmented as Purity: >99%, Purity: >98% and Purity: >97%. Based on the application it is divided into Pancreatic Neuroendocrine Tumors, Kidney cancer and gastrointestinal stromal tumour. The Sunitinib Malate Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
The major driving factors of Sunitinib Malate Market are as follows:
Availability of a limited number of drug therapeutic options for the treatment of advanced pancreatic neuroendocrine tumors
Growing incidence of pancreatic cancer
Poor diagnosis rate in the early stages of pancreatic cancer
The major restraining factors of Sunitinib Malate Market are as follows:
Lot of side effects
High cost of sutent
The major opportunities of Sunitinib Malate Market are as follows:
Rising Scope for Cancer Therapy, Systematic Drugs under Pipeline and increasing awareness towards Carcinoma
The Sunitinib Malate Market has been segmented as below:
By Product:
Purity: >99%
Purity: >98%
Purity: >97%
By Application:
Pancreatic Neuroendocrine Tumors
Kidney Cancer
Gastrointestinal stromal Tumour
By Regional Analysis:
North America
Europe
Asia-Pacific
Rest of the World
Sunitinib Malate is the small molecule, orally bioavailable malate salt of an indolinone-based multi-focused on receptor tyrosine kinase (RTK) inhibitor that was affirmed by the Food and Drug Administration (FDA) for the treatment of Carcinoma. The conceivable antineoplastic movement of Sunitinib has figured out how to it being seen as a viable specialist in hindering cell multiplication and angiogenesis. Sunitinib cases have been endorsed for use in treatment of Pancreatic Neuroendocrine Tumors, Kidney Cancer and Gastrointestinal Stromal Tumour (GIST).
This report provides:
1) An overview of the global market for Sunitinib Malate Market and related technologies.
2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.
3) Identifications of new market opportunities and targeted promotional plans for Sunitinib Malate Market
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
Report Scope:
The scope of the report includes a detailed study of Sunitinib Malate Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer, Topcarepharm, Njfirstpharm, J&K Scientific and Targetmol. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
Reasons to Buy this Report:
Obtain the most up to date information available on all Sunitinib Malate Market.
Identify growth segments and opportunities in the industry.
Facilitate decision making on the basis of strong historic and forecast of Sunitinib Malate Market.
Assess your competitor’s refining portfolio and its evolution.
Request Sample Report from here: https://www.marketresearchengine.com/sunitinib-malate-market
Table of Contents:
Introduction
Research Methodology
Report Summary
Market Overview
4.1 Introduction
4.2 Drivers
4.3 Restrains
4.4 Industry Trends
4.5 Porter’s Five Forces Analysis
Sunitinib Malate Market Analysis, By Product
Sunitinib Malate Market Analysis, By Application
Sunitinib Malate Market Analysis, By Region
Competitive Overview
Company Profiles
9.1 Pfizer
9.2 Topcarepharm
9.3 Njfirstpharm
9.4 J&K Scientific
9.5 Targetmol
Other Related Market Research Reports:
Blood Clot Preventive Drugs Market Growth, Future Prospects and Competitive Analysis, 2018-2024
Blood Plasma Market is Forecast to Cross US$ 44.0 Billion by 2024
Contact Info:
Name: John Bay
Email: Send Email
Organization: Market Research Engine
Website: https://www.marketresearchengine.com/
Release ID: 442761
Google
RSS